Interaction of native and modified low-density lipoproteins with extracellular matrix

Current Opinion in Lipidology

Volumn 11, Issue 5, 2000, Pages 457-463

  Chait, Alan ^a   Wight, Thomas N ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN; CYTOKINE; ENZYME; GROWTH FACTOR; LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN; PROTEOGLYCAN;

ARTERY WALL; ATHEROGENESIS; ATHEROSCLEROSIS; EXTRACELLULAR MATRIX; HYPOTHESIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN MODIFICATION; PROTEIN STRUCTURE; REVIEW;

ANIMALS; APOLIPOPROTEINS; ARTERIOSCLEROSIS; EXTRACELLULAR MATRIX; HUMANS; LIPOPROTEINS, LDL; MATRIX METALLOPROTEINASE 1; MODELS, CARDIOVASCULAR; PROTEIN BINDING; PROTEOGLYCANS;

EID: 0033780009     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-200010000-00003     Document Type: Review

References (63)

1. The response-to-retention hypothesis of early atherogenesis
2. The participation of aortic proteins in the formation of complexes between low density lipoproteins and intima-media extracts
3. Characterization and properties of a lipoprotein-complexing proteoglycan from human aorta
4. Interaction of serum lipoproteins and a proteoglycan from bovine aorta
5. The response-to-retention hypothesis of atherogenesis reinforced
6. Remnant lipoprotein metabolism: Key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E
7. Lipoprotein lipase enhances the interaction of low density lipoproteins with artery-derived extracellular matrix proteoglycans
8. Lipoprotein modification: Cellular mechanisms
9. The role of oxidized LDL in the atherogenic process
10. Identification of the principal proteoglycan-binding site in LDL: A single point mutation in apolipoprotein B100 severely affects proteoglycan interaction without affecting LDL receptor binding
11. Identification of apo B-100 segments mediating the interaction of low density lipoproteins with arterial proteoglycans
12. The NH2-terminal region of apolipoprotein B is sufficient for lipoprotein association with glycosaminoglycans
13. Susceptibility to atherosclerosis in mice expressing exclusively apolipoprotein B48 or apolipoprotein B100
14. Influence of plasma lipid and LDL-subfraction profile on the interaction between low density lipoprotein with human arterial wall proteoglycans
15. Differences in carbohydrate content of low density lipoproteins associated with low density lipoprotein subclass patterns
16. Interaction of low density lipoproteins with arterial proteoglycans: The role of charge and sialic acid content
17. Sialic acid-containing components of lipoproteins influence lipoprotein-proteoglycan interactions
18. Proteoglycans contribution to association of Lp(a) and LDL with smooth muscle cell extracellular matrix
19. Comparison of apolipoprotein and proteoglycan deposits in human coronary atherosclerotic plaques: Co-localization of biglycan with apolipoproteins
20. Structural determinants in the C-terminal domain of apolipoprotein E mediating binding to the protein core of human aortic biglycan
21. Lipoprotein lipase is synthesized by macrophage-derived foam cells in human coronary atherosclerotic plaques
22. Lipoprotein lipase increases low density lipoprotein retention by subendothelial cell matrix
23. Lipoprotein lipase enhances the binding of native oxidized low density lipoproteins to versican and biglycan synthesized by cultured arterial smooth muscle cells
24. Lipoprotein lipase (LPL) strongly links native and oxidized low density lipoprotein particles to decorin-coated collagen. Roles for both dimeric and monomeric forms of LPL
25. Oxidation-specific epitopes in human coronary atherosclerosis are not limited to oxidized low-density lipoprotein
26. Low density lipoprotein undergoes oxidative modification in vivo
27. Oxidation of low density lipoprotein particles decreases their ability to bind to human aortic proteoglycans
28. Mild oxidation of lipoproteins increases their affinity for surfaces covered by heparan sulfate and lipoprotein lipase
29. Plasma apolipoprotein A-I, A-II, B, C-I and E are glycosylated in hyperglycemic diabetic subjects
30. Glycation of apolipoprotein E impairs its binding to heparin: Identification of the major glycation site
31. Glycation of plasma low density lipoproteins increases interaction with arterial proteoglycans
32. Interaction of low density lipoproteins with human aortic elastin
33. In vitro interactions of oxidatively modified LDL with type I, II, III, IV, and V collagen, laminin, fibronectin, and poly-D-lysine
34. Interaction between fibronectin, proteoglycans and lipoproteins
35. Interaction of lipoprotein(a) with fibronectin and its potential role in atherogenesis
36. Oxidation of high-density lipoprotein HDL3 leads to exposure of apo-AI and apo-AII epitopes and to formation of aldehyde protein adducts, and influences binding of oxidized low-density lipoprotein to type I and type III collagen in vitro
37. Interaction of native and cell-modified low density lipoprotein with collagen gel
38. Decorin links low-density lipoproteins (LDL) to collagen: A novel mechanism for retention of LDL in the atherosclerosis plaque
39. Molecular basis for the association of group IIA phospholipase A2 and decorin in human atherosclerotic lesions
40. Phospholipase A2 type II binds to extracellular matrix biglycan: Modulation of its activity on LDL by colocalization in glycosaminoglycan matrixes
41. Lipolytic modification of LDL by phospholipase A2 induces particle aggregation in the absence and fusion in the presence of heparin
42. Rabbit aorta and human atherosclerotic lesions hydrolyze the sphingomyelin of retained low-density lipoprotein. Proposed role for arterial-wall sphingomyelinase in subendothelial retention and aggregation of atherogenic lipoproteins
43. Sphingomyelinase, an enzyme implicated in atherogenesis, is present in atherosclerotic lesions and binds to specific components of the subendothelial extracellular matrix
44. Sphingomyelinase induces aggregation and fusion, but phosphilipase A2 only aggregation, of low density lipoprotein (LDL) particles. Two distinct mechanisms leading to increased binding strength of LDL to human aortic proteoglycans
45. Biosynthesis of proteoglycans
46. Oxidized low density lipoproteins regulate synthesis of monkey aortic smooth muscle cell proteoglycans that have enhanced native low density lipoprotein binding properties
47. Effects of platelet-derived growth factor and transforming growth factor, beta1 on the synthesis of a large versican-like chondroitin sulfate proteoglycan by arterial smooth muscle cells
48. Platelet derived growth factor and transforming growth factor-beta1 differentially affect the synthesis of biglycan and decorin by monkey arterial smooth muscle cells
49. Binding of low density lipoproteins by proteoglycans synthesized by proliferating and quiescent human arterial smooth muscle cells
50. Low-density lipoprotein stimulates mesangial cell proteoglycan and hyaluronan synthesis
51. Fatty acids modulate the composition of extracellular matrix in cultured human arterial smooth muscle cells by altering the expression of genes for proteoglycan core proteins
52. Effect of hypoxia and hypoxia/reoxygenation on proteoglycan metabolism by vascular smooth muscle cells
53. Apolipoprotein E containing high density lipoprotein stimulates endothelial production of heparan sulfate rich in biologically active heparin-like domains. A potential mechanism for the anti-atherogenic actions of vascular apolipoprotein E
54. The heparin-binding proteins apolipoprotein E and lipoprotein lipase enhance cellular proteoglycan production
55. Lysolecithin-induced alteration of subendothelial heparan sulfate proteoglycans increases monocyte binding to matrix
56. Inhibition of vascular smooth muscle cell migration by heparin-like glycosaminoglycans
57. Heparin causes the accumulation of heparan sulfate in cultures of arterial smooth muscle cells
58. Oxidized LDL stimulates matrix metalloproteinase-1 expression in human vascular endothelial cells
59. Inflammatory cytokines and oxidized low density lipoproteins increase endothelial cell expression of membrane type 1-matrix metalloproteinase
60. Membrane type 1 matrix metalloproteinase expression in human atherosclerotic plaques: Evidence for activation by proinflammatory mediators
61. Oxidized low-density lipoprotein regulates matrix metalloproteinase-9 and its tissue inhibitor in human monocyte-derived macrophages
62. Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: A potential mechanism of lesion stabilization